Breaking News Bar

Business News and Information

Viela Bio secures $75M Series B round. It's getting closer to bringing its lead candidate to market.

The biotech expects to use the funding to support its Biologics License Application with the FDA for inebilizumab.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear